Streetbeat News

Products Services

TNXP

Tonix Pharmaceuticals plans to expand the development and partnering of Tonmya in Japan and China for the management of fibromyalgia. The company will file a CTN in Japan and an IND in China, leveraging U.S. Phase 3 data without dosage adjustment. Tonmya's market exclusivity in Asia is supported by issued patents, and a U.S. FDA NDA submission is planned for the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:07 pm

AMRX

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has entered into an exclusive licensing agreement with Zambon Biotech SA for the commercialization of IPX203, a novel Parkinson's disease treatment, in Europe. IPX203 is under review by the U.S. FDA and aims to improve the lives of over 10 million people worldwide with Parkinson's. This agreement is part of Amneal's strategy to make IPX203 available globally, following a similar agreement for Canada and Latin America with Knight Therapeutics Inc.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:06 pm

NDRA

ENDRA Life Sciences Inc. (NASDAQ:NDRA) has installed its first TAEUS liver system in the UK at King's College Hospital NHS Foundation Trust for a clinical study. The study aims to compare the TAEUS technology's liver fat assessment accuracy with MRI. This partnership could potentially expand ENDRA's presence in the UK's NHS network, aligning with its goal to enhance healthcare delivery.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:06 pm

SNAL

Snail, Inc. (NASDAQ:SNAL), a leading developer and publisher of digital entertainment, announced the integration of AI technology into its game development process. This strategic move introduces advancements like text-to-3D model technology and the generation of resources and biomes on a planetary scale, aiming to enhance development efficiency and create more immersive gaming worlds. The company emphasizes a player-first approach, with recent initiatives like Zombie Within and the ARK Survival Ascended's Premium Mods program showcasing their commitment to innovation and community engagement.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:05 pm

PTLO

Portillo's has announced plans to open at least nine new restaurants in FY24, with commodity inflation expected to range from 4% to 6%. For 2025, the company targets at least 12% new restaurant growth, with a long-term outlook of approximately 12% to 15% annual new restaurant growth.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:05 pm

ELWS

Earlyworks Co., Ltd. (NASDAQ:ELWS), a Japanese company with proprietary blockchain technology, has partnered with NTT DOCOMO to co-create MetaMe, a meta-communication service. MetaMe aims to connect users through shared values and individual expressions, facilitated by blockchain technology for exclusive items and events. The service will feature a 'MetaMe NFT Market' for trading limited edition items and NFTs, enhancing user experience and community engagement.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 1:01 pm

LILM

Lilium announced it raised $292M in additional capital in 2023, received its first pre-delivery payments for the Lilium Jet ahead of expectations, and reported cash consumption below guidance.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:47 pm

ABBV

GMAB

Genmab and AbbVie announced that the FDA has granted priority review for their supplemental Biologics License Application for epcoritamab-bysp, aimed at treating relapsed/refractory follicular lymphoma after two or more lines of systemic therapy.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:47 pm

TGTX

TG Therapeutics announced the issuance of three additional US patents for Briumvi, a treatment for relapsing forms of multiple sclerosis, which can now be administered in a one-hour infusion following the starting dose. This development could enhance the drug's marketability and patient convenience, potentially impacting TG Therapeutics' market position positively.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:35 pm

CMND

Clearmind Medicine has submitted three additional international patent applications for innovative compounds related to MDMA, Ibogaine, and Ketamine. This move signifies the company's ongoing efforts to expand its intellectual property portfolio in the psychedelic medicine space.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 12:30 pm